Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | MPO | P05164 | 2/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | AHR | P35869 | 1/20 | 0.65 |
| ▸ | GCGR | P47871 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verazide SCHEMBL564065 | 0.90 | MPO (0.82) | GAAMPONT5EKDM4EMAPT | |
| Verazide SCHEMBL28784283 | 0.90 | MPO (0.82) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL944141 | 0.88 | GAA (1.00) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL944135 | 0.88 | GAA (1.00) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL28515502 | 0.88 | GAA (0.81) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL11157751 | 0.88 | GAA (1.00) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL28515978 | 0.87 | GAA (0.81) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL12443144 | 0.87 | GAA (0.77) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL18642552 | 0.86 | GAA (0.80) | GAAMPONT5EKDM4EMAPT | |
| SCHEMBL18642551 | 0.86 | GAA (0.80) | GAAMPONT5EKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| CN-105492004-A | Method of treating topical microbial infections | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| CN-105492005-A | Methods of treating microbial infections including mastitis | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| CN-105263477-A | Compositions and associated methods for radioisotope-binding microparticles | BIOSPHERE MEDICAL INC | 2016-01-20 | — | — | CN | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| CN-104857515-A | Controlled release dosing medicine core composition and osmotic pump preparation comprising medicine core composition | SHANGHAI INST MATERIA MEDICA | 2015-08-26 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014121342-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA PTY LIMITED (AU) | 2014-08-14 | — | — | WO | claimed |
| CN-102357249-A | Medicine for inhibiting medicine-resistant tubercle bacillus | GUANGZHOU HEALTH MEDICINE DEV CO LTD | 2012-02-22 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1134278-A | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method | CONG FANZI (CN) | 1996-10-30 | — | — | CN | claimed |
| EP-0609460-A1 | PHARMACEUTICAL AGENT WITH ANTITUMORAL ACTIVITY | KISLYAKOVA, Nonna Dmitrievna (RU) | 1994-08-10 | — | — | EP | claimed |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | UNIV EMORY (US) | 2026-03-26 | — | — | US | disclosed |
| US-12509714-B2 | Multiple heteroresistance to guide combination antibiotic regimens | EMORY UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| CN-115884687-A | Natural flavoring agent and natural smoke flavoring agent for enhancing function of buffering organic acid and preparation method thereof | 凯瑞卢森堡有限责任公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-4095162-A1 | APPLICATION OF AND PREPARATION METHOD FOR CATIONIC POLYMER MODIFIED BY FLUORINE-CONTAINING COMPOUND AS DRUG CARRIER | Soochow University (CN) | 2022-11-30 | — | — | EP | disclosed |
| US-11491105-B2 | Methods of treating microbial infections, including mastitis | Luoda Pharma Limited (IE) | 2022-11-08 | — | — | US | disclosed |
| US-20220273806-A1 | USE OF FLUORINE-CONTAINING COMPOUND-MODIFIED CATIONIC POLYMER AS DRUG CARRIER AND PREPARATION METHOD | SOOCHOW UNIVERSITY (CN) | 2022-09-01 | — | — | US | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210348207-A1 | Multiple Heteroresistance to Guide Combination Antibiotic Regimens | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-11 | — | — | US | disclosed |
| EP-2991968-B1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2021-11-10 | — | — | EP | disclosed |
| US-20210215696-A1 | Using Multiple Heteroresistance to Guide Combination Antibiotic Regimens | EMORY UNIVERSITY | 2021-07-15 | — | — | US | disclosed |
| EP-2953623-B1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA LTD (IE) | 2021-06-30 | — | — | EP | disclosed |
| US-10933048-B2 | Compounds and methods of treating bacterial infections | ULTUPHARMA AB (SE) | 2021-03-02 | — | — | US | disclosed |
| US-20200138777-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ULTUPHARMA AB (SE) | 2020-05-07 | — | — | US | disclosed |
| WO-2020061553-A1 | USING MULTIPLE HETERORESISTANCE TO GUIDE COMBINATION ANTIBIOTIC REGIMENS | EMORY UNIVERSITY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-10471043-B2 | Compounds and methods of treating bacterial infections | ULTUPHARMA AB (SE) | 2019-11-12 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | disclosed |
| US-10370341-B2 | Compounds and methods of treating infections | NEOCULI PTY LTD (AU) | 2019-08-06 | — | — | US | disclosed |
| EP-2991638-B1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2019-06-26 | — | — | EP | disclosed |
| US-10253002-B2 | Compounds and methods of treating infections | NEOCULI PTY LTD (AU) | 2019-04-09 | — | — | US | disclosed |
| US-20190084941-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2019-03-21 | — | — | US | disclosed |
| US-20180360802-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ULTUPHARMA AB (SE) | 2018-12-20 | — | — | US | disclosed |
| EP-3383857-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | Ultupharma AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| US-9943500-B2 | Methods of treating topical microbial infections | LUODA PHARMA PTY LTD (AU) | 2018-04-17 | — | — | US | disclosed |
| US-9775818-B2 | Methods for treating bacterial infections | NEOCULI PTY LTD (AU) | 2017-10-03 | — | — | US | disclosed |
| US-9750727-B2 | Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment | JOINT STOCK COMPANY “PHARMASYNTEZ” (RU) | 2017-09-05 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017095319-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ULTUPHARMA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| US-20170071884-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2017-03-16 | — | — | US | disclosed |
| CN-106456726-A | Biomarker directed multi-target immunotherapy | 阿德瓦希斯公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9539223-B2 | Methods for treating bacterial infections | NEOCULI PTY LTD (AU) | 2017-01-10 | — | — | US | disclosed |
| CN-105492004-A | Method of treating topical microbial infections | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | disclosed |
| CN-105492005-A | Methods of treating microbial infections including mastitis | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | disclosed |
| US-20160075665-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2016-03-17 | — | — | US | disclosed |
| EP-2991638-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | Neoculi Pty Ltd (AU) | 2016-03-09 | — | — | EP | disclosed |
| EP-2991968-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2016-03-09 | — | — | EP | disclosed |
| US-20160058717-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2016-03-03 | — | — | US | disclosed |
| CN-105263477-A | Compositions and associated methods for radioisotope-binding microparticles | BIOSPHERE MEDICAL INC | 2016-01-20 | — | — | CN | disclosed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | disclosed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | disclosed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | disclosed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | disclosed |
| CN-105147679-A | Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment | PHARMASYNTEZ | 2015-12-16 | — | — | CN | disclosed |
| CN-104857515-A | Controlled release dosing medicine core composition and osmotic pump preparation comprising medicine core composition | SHANGHAI INST MATERIA MEDICA | 2015-08-26 | — | — | CN | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| CN-104524422-A | Pill for treating gynecomastia and preparation method thereof | NIU ZHAOXIA | 2015-04-22 | — | — | CN | disclosed |
| WO-2014176636-A9 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014176634-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014176636-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2014-11-06 | — | — | WO | disclosed |
| CN-101146528-B | pharmaceutical composition comprising hydroxylated nebivolol | MYLAN LABORATORIES, INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| WO-2014121342-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA PTY LIMITED (AU) | 2014-08-14 | — | — | WO | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| CN-101175482-B | Abuse-proofed dosage form | GRUENENTHAL GMBH | 2013-09-18 | — | — | CN | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| CN-101450056-B | New use of sodium ion channel blocker in treating biology drug resistance of antibiotic | JIANGSU HONGJINTIAN PHARMACEUTICAL CO LTD | 2013-04-24 | — | — | CN | disclosed |
| US-20130052265-A1 | TUBERCULOSIS DRUG BASED ON 4-THIOUREIDO-IMINOMETHYLPYRIDINIUM PERCHLORATE: METHOD OF PREPARATION AND TREATMENT | JOINT STOCK COMPANY "PHARMASYNTEZ" (RU) | 2013-02-28 | — | — | US | disclosed |
| EP-2560630-A2 | TUBERCULOSIS DRUG BASED ON 4-THIOUREIDO-IMINOMETHYLPYRIDINIUM PERCHLORATE: METHOD OF PREPARATION AND TREATMENT | Joint Stock Company "Pharmasyntez" (RU) | 2013-02-27 | — | — | EP | disclosed |
| CN-102940634-A | Isoniazid-anethol trithione composition and its oral preparation | HAINAN WEIKANG PHARM QIANSHAN | 2013-02-27 | — | — | CN | disclosed |
| CN-102940637-A | Isoniazid-rifampicin-anethol trithione composition and its oral preparation | HAINAN WEIKANG PHARM QIANSHAN | 2013-02-27 | — | — | CN | disclosed |
| CN-102844024-A | Tuberculosis medicine based on 4-thioureido-iminomethylpyridinium perchlorate and preparation and treatment method thereof | PHARMASYNTEZ | 2012-12-26 | — | — | CN | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-102727496-A | Compound antituberculosis drug oral solid preparation and its preparation method | SHANGHAI SHUANGJIAN MODERN PHARMACEUTICAL TECHNOLOGY CONSULTING CO LTD | 2012-10-17 | — | — | CN | disclosed |
| CN-101856337-B | Novel penetration and controlled-release medicament delivery system and preparation method thereof | SHANGHAI INST MATERIA MEDICA | 2012-10-03 | — | — | CN | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| CN-102357249-A | Medicine for inhibiting medicine-resistant tubercle bacillus | GUANGZHOU HEALTH MEDICINE DEV CO LTD | 2012-02-22 | — | — | CN | disclosed |
| WO-2011132114-A9 | TUBERCULOSIS DRUG BASED ON 4-THIOUREIDO-IMINOMETHYLPYRIDINIUM PERCHLORATE: METHOD OF PREPARATION AND TREATMENT | JOINT STOCK COMPANY "PHARMASYNTEZ" (RU) | 2012-01-26 | — | — | WO | disclosed |
| CN-1656222-B | Antisense IAP nucleobase oligomers and uses thereof | Agra therapy (CA) | 2011-11-30 | — | — | CN | disclosed |
| WO-2011132114-A2 | TUBERCULOSIS DRUG BASED ON 4-THIOUREIDO-IMINOMETHYLPYRIDINIUM PERCHLORATE: METHOD OF PREPARATION AND TREATMENT | JOINT STOCK COMPANY "PHARMASYNTEZ" (RU) | 2011-10-27 | — | — | WO | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| CN-1989966-B | Pharmaceutical composition comprising rifamoin and isoniazid | CHONGQING HUAPONT PHARM CO LTD | 2011-06-08 | — | — | CN | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| CN-101856337-A | Novel penetration and controlled-release medicament delivery system and preparation method thereof | SHANGHAI INST MATERIA MEDICA | 2010-10-13 | — | — | CN | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-100571701-C | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2009-12-23 | — | — | CN | disclosed |
| CN-100563637-C | A kind of medicated core compositions of controlled release drug administration and controlled release preparation and preparation method thereof | BEIJING HONGLIN PHARMACEUTICAL (CN) | 2009-12-02 | — | — | CN | disclosed |
| CN-101450056-A | New use of sodium ion channel blocker in treating biology drug resistance of antibiotic | SHENZHEN HONGJINTIAN BIOTECHNO (CN) | 2009-06-10 | — | — | CN | disclosed |
| CN-100493547-C | Decoction for treating tuberculosis | SILIN YAN (CN) | 2009-06-03 | — | — | CN | disclosed |
| CN-101374532-A | Use of gallium for treating biofilm-associated infections | TITAN PHARMACEUTICALS INC (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101242827-A | Compositions comprising nebivolol | MYLAN LAB INC (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-101175482-A | Abuse-proofed dosage form | GRUENENTHAL GMBH (DE) | 2008-05-07 | — | — | CN | disclosed |
| US-20080089937-A1 | Controlled release drug compositions and preparation methods | OCEAN STAR INTERNATIONAL, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| CN-101161242-A | A explosive core composition of controlled release administer drug and controlled release preparation as well as its preparing method | BEIJING HONGLIN PHARMACEUTICAL (CN) | 2008-04-16 | — | — | CN | disclosed |
| CN-101146528-A | Pharmaceutical composition comprising hydroxylated nebivolol | MYLAN LAB INC (US) | 2008-03-19 | — | — | CN | disclosed |
| CN-101132776-A | Stable tablet formulation of tetrahydrobiopterin | BIOMARIN PHARM INC (US) | 2008-02-27 | — | — | CN | disclosed |
| WO-2008017840-A1 | CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | MERLION PHARMACEUTICALS SA (CH) | 2008-02-14 | — | — | WO | disclosed |
| CN-101103969-A | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-01-16 | — | — | CN | disclosed |
| CN-1989966-A | Pharmaceutical composition comprising rifamoin and isoniazid | CHONGQING HUABANG PHARMACY LTD (CN) | 2007-07-04 | — | — | CN | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| CN-1957947-A | Product for preventing and curing illeffect of antituberculosis drugs, and fabricating method | YAN HUAIWEI (CN) | 2007-05-09 | — | — | CN | disclosed |
| CN-1957951-A | Product for preventing and curing tuberculosis in assistance, and anti toxin and side effects of tuberculosis, and preparation method | YAN HUAIWEI (CN) | 2007-05-09 | — | — | CN | disclosed |
| WO-2007017114-A1 | NEW SUBSTITUTED AZATHYMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | MERLION PHARMACEUTICALS SA (CH) | 2007-02-15 | — | — | WO | disclosed |
| CN-1882375-A | treatment of amyloid-and epileptogenesis-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-12-20 | — | — | CN | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| CN-1753675-A | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-03-29 | — | — | CN | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| CN-1613491-A | Decoction for treating tuberculosis | YAN SILIN (CN) | 2005-05-11 | — | — | CN | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| CN-1302290-A | Selective anti-mycobacterial preparations, method for producing the same and pharmaceutical compositions | INST ORCH SINTEZA URAL OTDEL R (RU) | 2001-07-04 | — | — | CN | disclosed |
| EP-1081131-A1 | SELECTIVE ANTI-MYCOBACTERIAL PREPARATIONS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS | Institut Organicheskogo Sinteza Uralskogo Otdeleniya Rossiiskoi Akademii Nauck (RU) | 2001-03-07 | — | — | EP | disclosed |
| CN-1134278-A | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method | CONG FANZI (CN) | 1996-10-30 | — | — | CN | disclosed |
| EP-0609460-A1 | PHARMACEUTICAL AGENT WITH ANTITUMORAL ACTIVITY | KISLYAKOVA, Nonna Dmitrievna (RU) | 1994-08-10 | — | — | EP | disclosed |
| EP-0609460-A1 | PHARMACEUTICAL AGENT WITH ANTITUMORAL ACTIVITY | KISLYAKOVA, Nonna Dmitrievna (RU) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084941-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | ELANE, IL1A, IL1B | GAA 318/4885MPO 37/4885NT5E 878/4885 |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | GAA 398/4885MPO 47/4885NT5E 568/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | GAA 2714/4885MPO 3313/4885NT5E 3696/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | GAA 1402/4885MPO 11/4885NT5E 3129/4885 |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | Q6ZSR9, AMPD2, AMPD1 | GAA 3797/4885MPO 696/4885NT5E 504/4885 |
| US-20220273806-A1 | USE OF FLUORINE-CONTAINING COMPOUND-MODIFIED CATIONIC POLYMER AS DRUG CARRIER AND PREPARATION METHOD | F12, SLCO4C1, SLC7A1 | GAA 2278/4885MPO 1384/4885NT5E 3661/4885 |
| US-10370341-B2 | Compounds and methods of treating infections | ELANE, IL1A, IL1B | GAA 318/4885MPO 37/4885NT5E 878/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | GAA 1255/4885MPO 1988/4885NT5E 2417/4885 |
| US-20180360802-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ELANE, TNF, IL1B | GAA 173/4885MPO 12/4885NT5E 1406/4885 |
| US-20160058717-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, PIGS, CAT | GAA 177/4885MPO 5/4885NT5E 435/4885 |
| US-20160075665-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | ELANE, IL1B, IL1A | GAA 423/4885MPO 29/4885NT5E 1323/4885 |
| US-20210348207-A1 | Multiple Heteroresistance to Guide Combination Antibiotic Regimens | POLI, SPOUT1, Q6ZSR9 | GAA 2117/4885MPO 2234/4885NT5E 686/4885 |
| US-20170071884-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, TNF, PIGS | GAA 171/4885MPO 5/4885NT5E 335/4885 |
| US-10471043-B2 | Compounds and methods of treating bacterial infections | ELANE, TNF, IL1B | GAA 173/4885MPO 12/4885NT5E 1406/4885 |
| US-10933048-B2 | Compounds and methods of treating bacterial infections | ELANE, TNF, NISCH | GAA 136/4885MPO 19/4885NT5E 1349/4885 |
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | GAA 949/4885MPO 128/4885NT5E 2498/4885 |
| US-20200138777-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ELANE, TNF, NISCH | GAA 136/4885MPO 19/4885NT5E 1349/4885 |
| US-11491105-B2 | Methods of treating microbial infections, including mastitis | LCT, TSLP, MLEC | GAA 1402/4885MPO 11/4885NT5E 3129/4885 |
| US-20210215696-A1 | Using Multiple Heteroresistance to Guide Combination Antibiotic Regimens | QTRT2, Q6ZSR9, SPOUT1 | GAA 1775/4885MPO 2797/4885NT5E 781/4885 |
| US-10253002-B2 | Compounds and methods of treating infections | ELANE, IL1A, IL1B | GAA 318/4885MPO 37/4885NT5E 878/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | GAA 2444/4885MPO 3192/4885NT5E 3855/4885 |
| US-12509714-B2 | Multiple heteroresistance to guide combination antibiotic regimens | Q6ZSR9, CLPP, PNKP | GAA 3403/4885MPO 2285/4885NT5E 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.